Clinical and Translational Allergy,
Год журнала:
2023,
Номер
13(10)
Опубликована: Окт. 1, 2023
Abstract
Background
Allergic
diseases—rhinitis
and
asthma—are
the
most
common
chronic
conditions
affecting
adults.
Traditional
approaches
to
allergy
diagnosis
treatment
do
not
meet
health
needs
of
all
patients.
Treatment
adherence
remains
a
challenge
for
physicians.
The
ubiquity
Internet
access
paired
with
limited
in‐person
contact
medical
personnel
in
course
COVID‐19
pandemic
demonstrated
potential
mHealth
communicating
information.
Body
abundance
new
applications
dedicated
various
specialties
encourages
reflection
on
informed
use
such
tools.
paper
takes
closer
look
at
presents
conclusions
selected
studies
focusing
good
apps.
strength
weakness
opportunities
threats
analysis
was
used
illustrate
strengths
strategy,
as
well
its
advantages,
limitations
areas
need
further
development.
Conclusion
depends
quality
quantity
collected
patient
data,
reliable
processing,
publication
outcomes
from
analyses.
Therefore,
it
is
necessary
promote
validated
among
patients,
physicians
staff.
Allergy,
Год журнала:
2023,
Номер
78(5), С. 1169 - 1203
Опубликована: Фев. 17, 2023
Asthma,
rhinitis,
and
atopic
dermatitis
(AD)
are
interrelated
clinical
phenotypes
that
partly
overlap
in
the
human
interactome.
The
concept
of
"one-airway-one-disease,"
coined
over
20
years
ago,
is
a
simplistic
approach
links
between
upper-
lower-airway
allergic
diseases.
With
new
data,
it
time
to
reassess
concept.
This
article
reviews
(i)
observations
led
Allergic
Rhinitis
its
Impact
on
Asthma
(ARIA),
(ii)
insights
into
polysensitization
multimorbidity,
(iii)
advances
mHealth
for
novel
phenotype
definitions,
(iv)
confirmation
canonical
epidemiologic
studies,
(v)
genomic
findings,
(vi)
treatment
approaches,
(vii)
concepts
onset
rhinitis
multimorbidity.
One
recent
concept,
bringing
together
diseases
with
skin,
gut,
neuropsychiatric
multimorbidities,
"Epithelial
Barrier
Hypothesis."
review
determined
"one-airway-one-disease"
does
not
always
hold
true
several
disease
can
be
defined.
These
include
an
extreme
"allergic"
(asthma)
combining
asthma,
conjunctivitis.
alone
asthma
multimorbidity
represent
two
distinct
following
differences:
transcriptomic
background
(Toll-Like
Receptors
IL-17
as
local
disease;
IL-33
IL-5
non-allergic
systemic
disease),
allergen
sensitization
patterns
(mono-
or
pauci-sensitization
versus
polysensitization),
severity
symptoms,
response.
In
conclusion,
(local
disease)
(systemic
should
considered
diseases,
possibly
modulated
by
microbiome,
may
model
understanding
epidemics
chronic
autoimmune
Clinical & Experimental Allergy,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 16, 2025
Adherence
to
rhinitis
treatment
has
been
insufficiently
assessed.
We
aimed
use
data
from
the
MASK-air
mHealth
app
assess
adherence
oral
antihistamines
(OAH),
intra-nasal
corticosteroids
(INCS)
or
azelastine-fluticasone
in
patients
with
allergic
rhinitis.
included
regular
European
users
self-reported
and
reporting
at
least
1
day
of
OAH,
INCS
azelastine-fluticasone.
assessed
weeks
during
which
answered
questionnaire
on
all
days.
restricted
our
analyses
provided
between
January
June,
encompass
pollen
seasons
across
different
countries.
analysed
symptoms
using
visual
analogue
scales
(VASs)
combined
symptom-medication
score
(CSMS),
performing
stratified
by
weekly
levels.
Medication
was
computed
as
proportion
days
reported
medication
use.
Sensitivity
were
performed
considering
most
missing
months
4
data.
8212
complete
(1361
users).
(use
>
80%
days)
specific
drug
classes
ranged
31.7%
for
38.5%
OAH.
Similar
found
without
asthma,
except
(better
asthma
patients).
VAS
CSMS
levels
increased
no
full
adherence,
INCS.
A
higher
uncontrolled
observed
adherence.
In
weeks,
41.2%
co-medication.
The
sensitivity
displayed
similar
results.
high
MASK-air.
Different
patterns
compared
OAH
that
are
likely
impact
guidelines.
Allergy,
Год журнала:
2023,
Номер
78(6), С. 1425 - 1440
Опубликована: Март 28, 2023
Abstract
Allergic
rhinitis
is
a
highly
prevalent
chronic
inflammatory
disorder
of
the
nasal
mucosa
that
poses
significant
burden
on
patients'
health
and
quality
life.
Current
therapies
for
allergic
are
unable
to
reinstate
immune
homeostasis
or
restricted
by
specific
allergens.
Potential
therapeutic
strategies
urgently
needed.
Mesenchymal
stem
cells
(MSCs)
immune‐privileged,
have
strong
immunomodulatory
effects,
can
be
easily
isolated
from
various
sources.
Thus,
MSC‐based
demonstrate
potential
treating
diseases.
Recently,
numerous
studies
investigated
effects
MSCs
in
animal
models
rhinitis.
Here,
we
review
mechanisms
airway
inflammation,
especially
rhinitis,
highlight
recent
research
regarding
modulation
cells,
discuss
clinical
therapy
The Journal of Allergy and Clinical Immunology In Practice,
Год журнала:
2024,
Номер
12(8), С. 2010 - 2016.e7
Опубликована: Март 22, 2024
In
the
recent
report
of
Organisation
for
Economic
Co-operation
and
Development
(OECD)
on
Best
Practices
(BPs)
Integrating
Care
to
Prevent
Manage
Chronic
Diseases,
an
app
rhinitis
asthma
(MASK-air
[Mobile
Airways
Sentinel
networK
airway
diseases])
has
been
listed.
The
OECD
is
a
reliable
source
evidence-based
policy
analysis
economic
data
largely
used
by
governments.
It
published
several
BPs
public
health.
On
May
10,
2023,
13
Diseases
in
European
Union.
did
not
cover
all
models
integrated
care;
rather,
it
"focuse(d)
those
that
are
key
strategic
interest
makers."
New
MASK-air
studies
(not
report)
include
equity,
usability
old-age
adults,
impact,
quality
life,
allergen
immunotherapy.
freely
available
iOS
Android
30
countries
recently
introduced
United
States.
BP
represents
model
digitally
enabled,
patient-centered
care
chronic
diseases
using
holistic
approach
shared
decision
making.
Allergy,
Год журнала:
2023,
Номер
78(11), С. 2835 - 2850
Опубликована: Июль 14, 2023
In
allergic
asthma
patients,
one
of
the
more
common
phenotypes
might
benefit
from
allergen
immunotherapy
(AIT)
as
add-on
intervention
to
pharmacological
treatment.
AIT
is
a
treatment
with
disease-modifying
modalities,
evidence
for
efficacy
based
on
controlled
clinical
trials
following
standardized
endpoint
measures.
However,
so
far
there
lack
consensus
endpoints
in
trials.
The
aim
task
force
(TF)
European
Academy
Allergy
and
Clinical
Immunology
(EAACI)
evaluating
several
outcome
measures
asthma.The
domains
asthmatic
patients
have
been
evaluated
this
position
paper
(PP):
(i)
exacerbation
rate,
(ii)
lung
function,
(iii)
ICS
withdrawal,
(iv)
symptoms
rescue
medication
use,
(v)
questionnaires
(PROMS),
(vi)
bronchial/nasal
provocation,
(vii)
exposure
chambers
(AEC)
(viii)
biomarkers.Exacerbation
rate
can
be
used
reliable
objective
primary
outcome;
however,
limited
due
different
definitions
exacerbation.
time
after
withdrawal
first
considered
measure.
Besides,
advantages
disadvantages
implications
further
are
elaborated
PP.This
EAACI-PP
aims
highlight
important
aspects
current
by
critically
their
applicability
AIT.
The Journal of Allergy and Clinical Immunology In Practice,
Год журнала:
2024,
Номер
12(10), С. 2648 - 2668.e2
Опубликована: Июль 4, 2024
The
traditional
healthcare
model
is
focused
on
diseases
(medicine
and
natural
science)
does
not
acknowledge
patients'
resources
abilities
to
be
experts
in
their
own
lives
based
lived
experiences.
Improving
safety,
quality,
coordination,
as
well
quality
of
life,
an
important
aim
the
care
patients
with
chronic
conditions.
Person-centered
needs
ensure
that
people's
values
preferences
guide
clinical
decisions.
This
paper
reviews
current
knowledge
develop
(1)
digital
pathways
for
rhinitis
asthma
multimorbidity
(2)
digitally
enabled,
person-centered
care.
